Cornelia Becker
4 Papers
Cornelia Becker is an academic researcher. The author has contributed to research in topics: Internal medicine & Multiple myeloma. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study
Song-Yau Wang,T. Holzhey,Simone Heyn,Thomas Zehrfeld,Susann Fricke,Franz Albert Hoffmann,Cornelia Becker,Leanthe Braunert,Thomas Edelmann,Inessa Paulenz,Marcus Hitzschke,Franziska Flade,Andreas Schwarzer,K. Fenchel,Georg-Nikolaus Franke,Vladan Vucinic,Madlen Jentzsch,Sebastian Schwind,Saskia Hell,Donata Backhaus,Thoralf Lange,Dietger Niederwieser,Markus Scholz,Uwe Platzbecker,Wolfram Pönisch +24 more
TL;DR: In this paper , a retrospective monocentric analysis included 540 patients with multiple myeloma (MM) who received an autologous stem cell transplantation (ASCT) between 1996 and 2019.
Stem cell mobilization and autologous stem cell transplantation after bendamustine, prednisone and bortezomib induction in multiple myeloma patients with renal impairment
Stephan Fricke,Su Wang,T. Holzhey,Madlen Holzvogt,Marc Andrea,Vladan Vucinic,Georg-Nikolaus Franke,Simone Heyn,Saskia Hell,B. Schetschorke,Madlen Jentzsch,Sebastian Schwind,Thomas Zehrfeld,Leanthe Braunert,Thomas Edelmann,Cornelia Becker,F. Hoffmann,Kolja Reifenrath,M Schwarz,Andreas Schwarzer,Franziska Flade,D. Hammerschmidt,Markus Scholz,Maximilian Merz,Uwe Platzbecker,Wolfram Pönisch +25 more
TL;DR: In this article , the authors analyzed the efficacy of a BPV induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM) patients depending on the severity of renal impairment.
Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis *
David W. Denning,Kieren A. Marr,W. Lau,D. Facklam,Voravit Ratanatharathorn,Cornelia Becker,Andrew J. Ullmann,Nita L. Seibel,Patricia M. Flynn,Jo Anne H. Van Burik,Donald N. Buell,Thomas F. Patterson +11 more
TL;DR: Micaf ungin as primary or salvage therapy proved efficacious and safe in high-risk patients with IA, although patient numbers are small in the micafungin-only groups.
Combined Bendamustine, Prednisone and Bortezomib (BPV) in Patients with Relapsed or Refractory Multiple Myeloma
W. Poenisch,Malvina Bourgeois,Barbara Moll,Simone Heyn,Nadja Jäkel,R. Rohrberg,H. Hurtz,Marion Schmalfeld,M. Assmann,Thomas Edelmann,Martin Mohren,Franz Albert Hoffmann,Andreas Schwarzer,Gerald Hensel,Kerstin Loeschcke,Cornelia Becker,Rainer Krahl,I. Wagner,Haifa Kathrin Al-Ali,D. Niederwieser +19 more
- 16 Nov 2012
TL;DR: BPV therapy was well tolerated in patients with relapsed/refractory MM, with a response rate of approximately 70 %, and the high efficacy and the favourable toxicity profile of BPV warrant further evaluation in clinical trials.